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Opioid antagonists may be useful 
in control of intractable pain 
in advanced disease. A case series
Abstract
Opioid antagonists naloxone and naltrexone administered in ultra low doses are able to control pain which 
originates from opioid induced pain facilitation or hyperalgesia. In this article we describe a series of pa-
tients with intractable pain treated compassionately with ultra low doses of naloxone or naltrexone. Most 
of the patients suffered of advanced cancer disease and were treated with high doses of opioids. However, 
one patient suffered of non-malignant pain and did not tolerate exogenous opioids at all. She responded to 
ultralow doses of naloxone and naltrexone alone suggesting that endogenous opioids may also play a role 
in pathological pain conditions. Basing on this case series we discuss current literature, trying to make sense 
out of plethora of negative and positive findings.
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Introduction
It is known for more than ten years that opio-
ids may not only inhibit pain transmission, but also, 
alongside, cause pain facilitation [1–4]. This phe-
nomenon is called opioid induced hyperalgesia (OIH). 
Numerous animal and human studies revealed that 
the mechanism of OIH is frequently related to the 
changes in opioid receptors from the inhibitory to 
the excitatory mode [5–7]. Opioid receptors in the 
excitatory mode are particularly sensitive to inhibition 
by picomolar while the opioid receptors in the in-
hibitory mode respond with inhibition to nanomolar 
concentrations of opioid antagonists [8]. Blocking of 
the opioid receptors in the excitatory mode can also 
be effectuated by cholera toxin [9] or inhibitors of 
neuraminidase [10]. OIH may be more common 
than previously expected [3, 11] and it may play 
an important role in development of tolerance to 
opioids 2 as well as in intractable pain [3]. Although 
this part of evidence is not controversial, the whole 
hypothesis was initially questioned by the variable 
and apparently contradicting results of clinical tri-
als using combinations of opioids and ultralow dose 
of opioid antagonists [12–14]. The “ultra low dose” 
of opioid antagonists used was not well defined and 
positive effects were reported with the wide range 
of doses. However, negative results tended to be re-
ported with relatively high doses of antagonists [15, 
16], which could also revert opioid analgesia. Nobody 
performed dose titration studies for opioid antago-
nists. Other reason of this conflicting evidence may 
be the phenomenon described by Crain and Shen 
suggesting, counter intuitively, that patients receiv-
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ing higher doses of opioids may respond to lower 
doses of antagonists [8]. According to this idea, the 
doses of antagonists needed to counteract OIH may 
be variable not only from person to person, but also 
within one person when the doses of opioids induc-
ing OIH are changed. In the clinical trial with large 
number of patients with ostheoarthritis using either 
placebo, oxycodone or oxycodone with two different 
doses of naltrexone, significantly improved analgesia 
was observed in patients receiving naltrexone twice 
daily but not four times daily and oxycodone im-
mediate release twice daily [17]. As the duration of 
analgesia induced by oxycodone is short, naltrexone 
induced analgesia even in the absence of oxycodone 
in the blood. This raises the issue of opioid antago-
nists being analgesic per se in the low doses even 
without the use of opioid analgesics. Unfortunately, 
the authors did not involve a control group with nal-
trexone alone. The combination of oxycodone with 
fixed dose of naltrexone (Oxytrex) is patented and 
there is a lot of published and unpublished clinical 
data which will probably be released when the drug 
will obtain a license [18–20]. 
OIH can be experienced anywhere on or in the 
body, and may be confused with neuropathic pain 
[21]. It is sometimes complicated by signs of neuro-
toxicity like delirium and drowsiness [11]. 
Based on the review of the literature we postu-
lated that some patients experiencing excruciating 
pain in advanced disease, despite high doses of 
opioids, may actually suffer of OIH. In the past seven 
years many patients experiencing this kind of pain 
were compassionately treated with ultra low dose 
of naloxone, 3 μg.kg–1.24 h SC, according to the 
internal protocol. Here we present patients who con-
tributed to our knowledge and experience. Several 
patients were treated by ZZ in the time he worked in 
the Netherlands. These observations combined with 
the data from literature should contribute to better 
understanding of the OIH phenomenon and help to 
develop future trial protocols.
Case no. 1 
A man aged 40 with pre-B-AL leukaemia was dis-
charged home after intensive treatment with chemo-
therapy. At discharge he had 25% of blast cells in 
his peripheral blood, thrombopenia and low back 
pain (intensity 8/10). His liver function was severely 
disturbed. The pain was treated with transdermal 
fentanyl 25 μg.h–1. Initially the pain intensity dropped 
to 3/10, but a week later increased to 7/10. The 
fentanyl dose was increased gradually to 150 μg.h–1 
over several weeks. Each upward adjustment of the 
dose of fentanyl was initially accompanied by im-
proved pain relief but each time, after one day, the 
pain was no better than before. The patient became 
restless and confused at night. When admitted as an 
inpatient, he had severe abdominal pain in the right 
upper quadrant and pain in his lower back (inten-
sity 9/10). A whole-body allodynia on light touch 
was noticed. While his fentanyl medication remained 
unchanged, a continuous SC infusion of naloxone 
200 μg.24 h–1 (3 μg.kg–1.24 h–1) was started. After 
4 hours pain intensity had decreased to 6/10, and 
after 24 hours to 2/10. The confusion cleared, and 
he returned home. The dose of naloxone remained 
unchanged and, although the pain remained control-
led, the backache became a problem. Gabapentin 
1800 mg/day successfully controlled this. He devel-
oped progressive paraparesis and paroxysms of high 
fever. He died without pain several days later.
Case no. 2 
A man aged 74 with liver metastases from colon 
cancer developed jaundice which was accompanied 
by severe abdominal right upper quadrant pain (in-
tensity 7/10), but no pruritus. A stent was introduced 
into the common bile duct, leading to a resolution 
of the jaundice. Because the liver pain persisted, he 
was prescribed oxycodone. The pain was relieved 
only partially by this, and for a few hours after 
each increase of the oxycodone dose. Within three 
weeks the dose reached 300 mg t.d.s. but the patient 
still scored the pain intensity 9/10. No cutaneous al-
lodynia or hyperalgesia was noticed. Surprisingly 
he was not constipated and his pupils were not 
constricted. Visceral OIH was suspected and the 
dose of oxycodone dose was arbitrally decreased to 
115 mg, t.d.s. A SC infusion of naloxone 200 μg.24 h–1 
(3 μg.kg–1.24 h–1) was started The intensity of liver 
pain decreased to 4/10 within 3 hours but pain in the 
lower back and lower abdomen became more ap-
parent (intensity 6/10). The naloxone dose was then 
titrated down to 166, 133 and 100 μg.24 h–1 (2,5, 
2,0 and 1,5 μg.kg–1.24 h–1, respectively). At this level 
he was pain free. After 1 week being on naloxone, 
a trial of decreasing the oxycodone dose to 100 mg 
t.d.s. caused immediate liver pain increase. So the 
oxycodone dose remained 115 mg t.d.s. Because 
of irritation at the infusion site, he was switched 
to an oral solution of naltrexone 0.01 μg.kg–1 o.d. 
(water solution made from crushed 50 mg tablets). 
Naltrexone at this dose was well tolerated but, to 
achieve satisfactory analgesia, the dose needed to 
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be titrated up to 0.015 mg.kg–1 o.d. At this dose 
pain in both locations was totally relieved (intensity 
0/10). The patient was able to work in his garden and 
enjoyed a short holiday overseas. After he returned 
he developed a gastro-intestinal obstruction which 
did not respond to standard medical management. 
He was sedated with drugs for his last three days. 
Case no. 3 
A woman aged 73 with known rectal cancer and 
liver metastases developed carcinomatous peritoni-
tis and bowel obstruction, for which she underwent 
surgery. After this she developed a diffuse lower 
abdominal pain, treated with transdermal fentanyl 
25 μg.h–1 and later 50 μg.h–1. The lower abdominal 
pain decreased, but she started to complain of 
pain in the right upper quadrant (intensity: 6/10). 
While her fentanyl medication remained unchanged, 
a continuous SC infusion of naloxone 200 μg.24 h–1 
(3 μg.kg–1.24 h–1 ) was started. After 3 hours the dose 
was lowered to 133 μg.24 h–1 (2 μg.kg–1.24 h–1) and 
the pain increased. Then the dose was adjusted to 
233 μg.24 h–1 (3.5 μg.kg–1.24 h–1) and both types of 
pain decreased to 0/10. She remained pain free until 
her death three weeks later.
Case no. 4
A retired plumber aged 65 had a mesothelioma 
of the right chest which had spread to the peri-
toneum despite chemotherapy and radiotherapy. 
Pain was treated with increasing doses of oxyco-
done SR tablets. Eventually, the patient was taking 
oxycodone 1 g/day but, because he became drowsy 
and confused, the dose was halved. Surprisingly, 
this resulted in a marked reduction in the pain. 
After several weeks, the pain increased again, and 
was maximal in the right hypochondrium. A par-
allel increase in medication resulted in a return 
of the drowsiness and confusion, and the patient 
was admitted as an inpatient in order to switch from 
oxycodone to methadone. Methadone was titrated 
up to 20 mg t.d.s. but this only partially relieved the 
pain. Higher doses were not well tolerated. A SC 
infusion of naloxone 3 μg.kg–1.24 h–1 was started, 
while the oxycodone remained unchanged. The pain 
decreased from 9 to 2/10. However, the respiratory 
rate decreased from 16/minute pre-naloxone to 
4/minute eight hours later. Reducing the dose to 
2.5 μg.kg–1.24 h–1 gave better analgesia, but the res-
piratory rate decreased at night again to 4/minute. 
Because of continuing concern, naloxone was discon-
tinued after three days. It was decided that, when 
the pain recurred, alternative treatment would be 
introduced. After 48 hours it became necessary to 
start a SC infusion of diamorphine 30–60 μg.24 h–1 
combined with ketamine 200 μg.24 h–1. Progressive 
sedation, but not analgesia, was achieved. The pa-
tient died a few days later.
Case no. 5
Female, 82 years old suffered in the past because 
disc prolaps with severe rheumatoid arthritis and os-
teoporosis. She was referred to anaesthesiologist be-
cause of severe pain in her thoraco-lumbar junction, 
experienced especially under her ribs. The vertebrae 
were tender on palpation and percussion and there 
was a marked hyperalgesia in the 12ths dermatome, 
more on the right than the left side. Before referral 
she was treated with a combination of Tramadol and 
Paracetamol. Epidural steroid injection had a doubt-
ful effect and was not repeated. Oxycodone caused 
severe constipation. Fentanyl was titrated up to 
75 μg.h–1 and was used together with low doses of 
oxycodone. Increase of Fentanyl helps every time 
for a while, but the beneficial effects wears off after 
several days. Besides pain the patient is hallucinat-
ing and agitated. Started with naloxone sc infusion 
2 μg.kg–1.24 h–1. The next day the pain is much 
less and the patient notice “to be clear in her head”. 
The pain is still present when she moves on the com-
mode, but at rest she is as good as pain free. She 
starts with naltrexone 10 μg per day. 
Case no. 6
A woman, 73 year old age suffered of severe pain 
due to bone metastases of breast cancer. Primary 
tumour was removed in 1993. She had undergone 
surgery and received radiotherapy afterwards. Ten 
years later she suffered severe pain and multiple 
bone-metastases were found on the bone scan. The 
X-rays showed pathological fractures of the pelvic 
bones. She was treated with radiotherapy. The pa-
tient become bed-bound and was admitted to the 
hospice. On arrival she was still in severe pain de-
spite paracetamol 1000 mg q.d.s., diclofenac 50 mg 
t.d.s. and morphine controlled release tablets 30 mg 
b.d. Morphine sulphate immediate release 10 mg 
tablets were used frequently because of insufficient 
analgesia. Morphine was replaced by oxycodone 
controlled release tablets 30 mg, b.d. with Diclofenac 
and Paracetamol provided more adequate analgesia. 
Within several days, the patient started to complain 
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of restlessness, lack of concentration, forgetful-
ness and sometimes confusion, especially in the nigh 
hours. Especially confusion, she was experiencing 
as frightening and intimidating. So despite of more 
adequate analgesia her quality of life was poor 
and highly unsatisfactory. Addition of haloperidol 
and later olanzapine did not change the situation. 
Naloxone 5 μg.kg–1.24 h–1 was started in a continu-
ous SC infusion. The next day patient reported that 
her mind had cleared up greatly and she felt much 
better. Notwithstandingly her pain had worsened. 
Consequently the dose of naloxon was lowered to 
3 μg.kg–1.24 h–1. The pain control improved again 
and after a few days the dose of Oxycodone could 
be reduced to 20 mg b.d. The patient remained clear. 
She became emotionally incontinent for a couple of 
days. She was crying and talking a lot. She discussed 
with her husband things that she would never dis-
cuss before. Four weeks later she told he doctor that 
this infusion, was the biggest miracle in her whole 
life and that we, doctors can never imagine how she 
suffered being in delirium. 
Case no. 7
An otherwise healthy obese women aged 45 suf-
fered since puberty from painful oedema on her 
legs. The subcutaneous tissue on both legs was al-
ways firm and tender. The pain was severe, con-
tinuous, and burning. Allodynia was apparent. Lym-
phoscintigraphy and Doppler examinations showed 
normal lymphatic and arterial circulation and only 
slight venous insufficiency in both legs. A diagno-
sis of lipoedema was suggested by a dermatologist. 
Paracetamol and NSAIDs did not relieve the pain. On 
several occasions she experienced poor tolerance of 
opioids (nausea and confusion) including tramadol, 
morphine, transdermal fentanyl and methadone. It 
seemed to her that the pain in her left leg increased 
whenever an opioid was prescribed. Ketamine-S, 
which she was using orally in the doses up to 30 mg 
daily was the only drug which was helpful. Because 
of its short supply, a trial of SC naloxone was un-
dertaken. Naloxone 300 μg.24 h–1 (3 μg.kg–1.24 h–1) 
was administered as a SC continuous infusion in an 
n = 1 placebo-controlled double-blind trial (Figure 1).
Local pharmacy prepared two identical syringes, 
one containing normal saline, second naloxone. Two 
syringes were kept by the pharmacy in the refrigera-
tor at +12oC pending the infusion. The trials took 
place on two days with one week washout in be-
tween. The patient was asked not to use ketamine-S 
for 24 hours before each infusion. During the first 
6 hours vital signs were measured hourly. The pain 
scores were explained to the patient and assessed 
by her hourly. Six hours later she went home and 
continued infusion for up to 24 hours and contin-
ued to record pain scores. Saline, given during the 
first trial day, did not have effect on her pain. Three 
hours after starting the naloxone infusion the pain 
intensity decreased and reached 0/10 by bedtime. It 
remained 0/10until a few hours after the end of the 
infusion. Then the pain returned, and she needed to 
use  extra doses of ketamine-S p.r.n. One week after 
the naloxone she started oral naltrexone solution 
0.02 μg.kg–1 o.d. Although she experienced consider-
able relief within hours, the naltrexone needed to be 
titrated up to 0.13 μg.kg–1 over 2 months in order to 
keep her pain free. With this dose the pain remained 
largely controlled. Nevertheless she experienced fre-
quent break-through pains which she was used to 
control with oral ketamine-S. Oral gabapentin up 
to the dose of 600 mg t.d.s. had no effect on her 
residual pain and was discontinued. At the time of 
writing, she has been taking naltrexone oral solu-
tion for 48 months. Naltrexone-induced bitter taste 
and anorexia have resulted in considerable weight 
loss (25 kg) — something she is still happy about, 
and definitely prefers to the pain.
Discussion
Opioid-induced hyperalgesia (OIH) is often re-
ferred to as part of opioid neurotoxicity [22]. Howev-
er, the latter term disguises the fact that, depending 
on circumstances, exogenous opioids may activate 
either pain-facilitatory or pain-inhibitory systems. 
OIH was first described with high doses of morphine 
administered either intrathecally [23] or intrave-
nously [24], and subsequently with oral medication 
[25]. OIH is also seen with other opioids, including 
ones structurally unrelated to morphine [26]. And, 
in this paper, cases are included where, seemingly, 
opioid-induced visceral hyperalgesia occurred in as-
sociation with fentanyl and oxycodone.
There is no doubt that addition of ultra low 
doses of antagonists, both naloxone and naltrex-
one is able to decrease some but not all adverse 
effects of opioids, and improve analgesia. How-
ever, as it was seen in several our patients, while 
one pain could be better controlled with advent of 
naloxone, other pains became worse. Theoretically, 
this means that some of the pains were related to 
hyperalgesia and were sensitive to naloxone, while 
others could be even reversed or unmasked by the 
same dose of the drug. This may add to confusion, 
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but also explain why several clinicat trials lacking 
specificity yielded negative results. In most of our 
patients the dose of naloxone was titrated against 
constant dose of the opioid. Indeed the effective 
dose of naloxone was in reciprocal relationship to 
the dose of opioid, similar to the suggestion made by 
Crain and Shen [8]. This means that the tablets con-
taining fixed ratio of oxycodone and naltrexone, 
may show in practice quite narrow pharmacologic 
window and the higher doses of these preparation 
may be ineffective.
Hypothetically, liver involved in pathological proc-
ess may produce a number of abnormal endog-
enous opioids [27]. These opioids may modify pain 
sensation and provide endogenous analgesia (One 
of such cases was reported by one of us (ZZ) recently 
in another context [28]), pruritus [29] but also hy-
peralgesia. In several our patients liver was clearly 
involved in the malignant process and could be the 
source of opioids causing hyperalgesia. However, hy-
peralgesia responding to opioid antagonists was also 
observed in patients with diseases unrelated to liver 
pathology and suggest that OIH was induced only 
by the exogenous opioids. In this context exceptional 
is the last case of young woman with chronic, poorly 
defined pain in her leg, responding paradoxically to 
exogenous opioids. Dramatic response to naloxone 
and naltrexone, but without any exogenous opioid 
suggest that, indeed, the OIH was of endogenous ori-
gin. However, we do not have any information about 
the functioning of her liver, which could suffer of 
adipositas. It is thus possible that many pain condi-
tions like in our patient remain undiagnosed and 
maltreated. 
Ultra low opioid antagonists seems to be effective 
in the symptoms classified as opioid neurotoxicity. 
Especially important and valued by the patients is the 
effect of naloxone on delirium and agitation. Cur-
rently, using the same protocol of sc naloxone infu-
sion, we treat many patients with terminal restless-
ness and agitation, allowing many patients to die 
without pain, peacefully with minimum of adverse 
effects of opioids. 
However, naloxone infusion can also have po-
tentially dangerous adverse effects. One of them 
is reversal of analgesia which is unpleasant but 
never dangerous. In one of our patients described 
above, naloxone infusion caused significant respira-
tory depression. This is consistent with the idea that 
respiratory depression of opioids is counteracted 
by the excitatory effect of opioids. This may explain 
why, respiratory depression is a problem only in 
the begin of therapy with opioids, but hardy ever 
causes problems later in the treatment.  Inhibition 
of the excitatory effect of the opioids by naloxone 
leaves the patient with the inhibitory effect only. 
Since we observed this kind of respiratory depression, 
we included measurement of respiratory rate in our 
protocol. It is important to diagnose early this condi-
tion and discontinue naloxone. This drug has a very 
short half life time and depression ceases within 
minutes. 
The bioavailability of naltrexone is approximately 
5% in humans [30–32]. After absorption which 
is nearly complete drug is transformed in the liver to 
active metabolite 6-beta-naltrexol [30, 33]. In severe 
liver cirrhosis the bioavailability of naltrexone will 
increase while synthesis of the active metabolite will 
diminish [34]. The pharmacokinetics of the ultralow 
dose is unknown. 
In the last years new data emerged suggesting 
that toll like receptors 4 (TLR4) localised in the spinal 
cord glia may be responsible for the phenomenon 
of opioid induced hyperalgesia [35–37]. These re-
ceptors can be activated in an astereospecific way 
by opioids [38]. Interestingly morphine-3- but not 
morphine-6-glucuronide are much more effective in 
stimulation of this receptors. This unravels a whole 
new world of possibilities. However, clinical proof of 
this concept is still lacking.
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